Mucosal leishmaniasis of the lips and cheeks: a first concomitant presentation of visceral and mucosal leishmaniasis in a patient living with HIV/AIDS in Monastir, Tunisia.
Humans
Male
Adult
Tunisia
Leishmaniasis, Visceral
/ drug therapy
HIV Infections
/ complications
Lip
/ pathology
Leishmaniasis, Mucocutaneous
/ drug therapy
Amphotericin B
/ therapeutic use
Antiprotozoal Agents
/ therapeutic use
Cheek
/ parasitology
Leishmania infantum
/ isolation & purification
AIDS-Related Opportunistic Infections
/ drug therapy
Treatment Outcome
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
03
08
2024
accepted:
27
09
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
Visceral Leishmaniasis (VL) is the most severe and fatal disease if left untreated. In people living with HIV/AIDS (PLHA), VL is considered an emerging opportunistic infection. The aim of this manuscript was to report a first case in Tunisia of a concomitant presentation of visceral and oral leishmaniasis in a patient LHA. A systematic review of the literature was performed according to PRISMA guidelines, as well. The patient, a 43-year-old heterosexual man, treated for HIV/AIDS was referred for macrocheilitis of the upper and lower lips. A noticeable nodular and painless swelling extending to the cheeks' mucosa was noted. The patient's poor oral hygiene was evident due to the presence of multiple dental caries. Histological analysis of the biopsied lower lip sample revealed the presence of numerous Leishmania amastigotes. The diagnosis of VL was clinically confirmed by the presence of a mild splenomegaly and pancytopenia and biologically by the identification of the parasite using PCR Lei and the species L. infantum involved using RFLP-PCR and culture. The treatment consisted of an intravenous administration of liposomal Amphotericin B (Ambisome®, 40 mg/kg/weight) for a period of 6 weeks. A favorable outcome was noted after one year with the resolution of clinical symptoms and a negative Leishmania blood PCR test. After 2 years, the patient remained asymptomatic but showed a positive Leishmania blood PCR test. Dolutegravir® was introduced in the patient's ART regimen. To the best of our knowledge, this is the first case report in Tunisia of atypical VL diagnosed through an uncommon oral location in an HIV/AIDS co-infected patient . Since VL is a severe and potentially fatal disease, it is essential for dentists to perform a thorough clinical examination and adopt a multidisciplinary approach in order to ensure an early diagnosis and an effective treatment outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Visceral Leishmaniasis (VL) is the most severe and fatal disease if left untreated. In people living with HIV/AIDS (PLHA), VL is considered an emerging opportunistic infection. The aim of this manuscript was to report a first case in Tunisia of a concomitant presentation of visceral and oral leishmaniasis in a patient LHA. A systematic review of the literature was performed according to PRISMA guidelines, as well.
CASE PRESENTATION
METHODS
The patient, a 43-year-old heterosexual man, treated for HIV/AIDS was referred for macrocheilitis of the upper and lower lips. A noticeable nodular and painless swelling extending to the cheeks' mucosa was noted. The patient's poor oral hygiene was evident due to the presence of multiple dental caries. Histological analysis of the biopsied lower lip sample revealed the presence of numerous Leishmania amastigotes. The diagnosis of VL was clinically confirmed by the presence of a mild splenomegaly and pancytopenia and biologically by the identification of the parasite using PCR Lei and the species L. infantum involved using RFLP-PCR and culture. The treatment consisted of an intravenous administration of liposomal Amphotericin B (Ambisome®, 40 mg/kg/weight) for a period of 6 weeks. A favorable outcome was noted after one year with the resolution of clinical symptoms and a negative Leishmania blood PCR test. After 2 years, the patient remained asymptomatic but showed a positive Leishmania blood PCR test. Dolutegravir® was introduced in the patient's ART regimen.
CONCLUSIONS
CONCLUSIONS
To the best of our knowledge, this is the first case report in Tunisia of atypical VL diagnosed through an uncommon oral location in an HIV/AIDS co-infected patient . Since VL is a severe and potentially fatal disease, it is essential for dentists to perform a thorough clinical examination and adopt a multidisciplinary approach in order to ensure an early diagnosis and an effective treatment outcome.
Identifiants
pubmed: 39443962
doi: 10.1186/s12981-024-00660-1
pii: 10.1186/s12981-024-00660-1
doi:
Substances chimiques
Amphotericin B
7XU7A7DROE
Antiprotozoal Agents
0
liposomal amphotericin B
0
Types de publication
Journal Article
Case Reports
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
73Informations de copyright
© 2024. The Author(s).
Références
WHO. Leishmaniasis. https://www.who.int/health-topics/leishmaniasis#tab=tab_1
WHO. Leishmaniasis: Key factors-2 March 2020. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
WHO. Leishmaniasis: Key factors- 12 January 2023. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
Derghal M, Tebai A, Balti G, et al. High-resolution melting analysis identifies reservoir hosts of zoonotic Leishmania parasites in Tunisia. Parasites Vectors. 2022;15:12. https://doi.org/10.1186/s13071-021-05138-x .
doi: 10.1186/s13071-021-05138-x
pubmed: 34996507
pmcid: 8742351
Passi D, Sharma S, Dutta S, Gupta C. Localised leishmaniasis of oral mucosa: report of an unusual clinicopathological entity. Case Rep Dent. 2014;2014: 753149. https://doi.org/10.1155/2014/753149 .
doi: 10.1155/2014/753149
pubmed: 25343050
pmcid: 4197891
Celentano A, Ruoppo E, Mansueto G, Mignogna MD. Primary oral leishmaniasis mimicking oral cancer: a case report. Br J Oral Maxillofac Surg. 2019;53(4):396–8. https://doi.org/10.1016/j.bjoms.2015.01.021 .
doi: 10.1016/j.bjoms.2015.01.021
Fleissig Y, Dan-Gur M, Michael-Gayego A, et al. A trespasser from a foreign land? A case report of primary mucosal leishmaniasis. BMC Infect Dis. 2022;22:212. https://doi.org/10.1186/s12879-022-07169-w .
doi: 10.1186/s12879-022-07169-w
pubmed: 35241005
pmcid: 8892399
Tabbabi A. Review of Leishmaniasis in the Middle East and North Africa. Afr Health Sci. 2019;19(1):1329–37. https://doi.org/10.4314/ahs.v19i1.4 .
doi: 10.4314/ahs.v19i1.4
pubmed: 31148958
pmcid: 6531937
Haouas N, Babba H. Leishmaniasis in Tunisia: History and New Insights into the Epidemiology of a Neglected Disease, The Epidemiology and Ecology of Leishmaniasis, David Claborn, IntechOpen, 2017. https://doi.org/10.5772/65000 . https://www.intechopen.com/books/the-epidemiology-and-ecology-of-leishmaniasis/leishmaniasis-in-tunisia-history-and-new-insights-into-the-epidemiology-of-a-neglected-disease
Aoun K, Jeddi F, Amri F, Ghrab J, Bouratbine A. Current epidemiological data on visceral leishmaniasis in Tunisia. Med Mal Infect. 2009;39(10):775–9.
doi: 10.1016/j.medmal.2009.08.010
pubmed: 19796895
WHO. Leishmaniasis and HIV co-infection. https://www.who.int/leishmaniasis/burden/hiv_coinfection/burden_hiv/coinfection/en/
Kallel K, Ammari L, Kaouech E, Belhadj S, Anane S, Kilani B, Chaker E. Asymptomatic bearing of Leishmania infantum among Tunisian HIV infected patients. Pathol Biol. 2007;55(10):521–4. https://doi.org/10.1016/j.patbio.2007.07.017 .
doi: 10.1016/j.patbio.2007.07.017
pubmed: 17888586
Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21:334–59. https://doi.org/10.1128/CMR.00061-07 .
doi: 10.1128/CMR.00061-07
pubmed: 18400800
pmcid: 2292576
Lindoso JAL, Moreira CHV, Mirella Alves Cunha MA, Queiroz IT. Visceral leishmaniasis and HIV coinfection: current perspectives. HIV/AIDS Res Palliat Care. 2018;10:193–201.
doi: 10.2147/HIV.S143929
Pagliano P, Esposito S. Visceral leishamiosis in immunocompromised host: an update and literature review. J Chemother. 2017. https://doi.org/10.1080/1120009X.2017.1323150 .
doi: 10.1080/1120009X.2017.1323150
pubmed: 28490252
Michiels JF, Monteil RA, Hofman P, Perrin C, Fuzibet JG, Lefichoux J, Loubière R. Oral leishmaniasis and Kaposi’s sarcoma in an AIDS patient. J Oral Pathol & Med. 1994;23:45–6.
doi: 10.1111/j.1600-0714.1994.tb00253.x
Diro E, Van Griensven J, Mohammed R, Colebunders R, Asefa M, Hailu A, Lynen L. Atypical manifestations of visceral leishmaniasis in patients with HIV in north Ethiopia: a gap in guidelines for the management of opportunistic infections in resource poor settings. Lancet Infect Dis. 2015;15:122–9.
doi: 10.1016/S1473-3099(14)70833-3
pubmed: 25300862
WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia, 7 June 2022. ( https://www.who.int/publications/i/item/9789240048294
Costa LDLN, Lima US, Rodrigues V, Lima MIS, Silva LA, Ithamar J, Azevedo CMPS. Factors associated with relapse and hospital death in patients coinfected with visceral leishmaniasis and HIV: a longitudinal study. BMC Infect Dis. 2023;23(1):141. https://doi.org/10.1186/s12879-023-08009-1 .
doi: 10.1186/s12879-023-08009-1
pubmed: 36882732
pmcid: 9993705
Spanakos G, Patsoula E, Kremastinou T, Saroglou G, Vakalis N. Development of a PCR-based method for diagnosis of Leishmania in blood samples. Mol Cell Probes. 2002;16(6):415–20.
doi: 10.1006/mcpr.2002.0436
pubmed: 12490142
Schönian G, Nasereddin A, Dinse N, Schweynoch C, Schallig HDFH, Presber W, et al. PCR diagnosis and characterization of Leishmania in local and imported clinical samples. Diag Microbiol Infect Dis. 2003;47(1):349–58.
doi: 10.1016/S0732-8893(03)00093-2
Chargui N, Haouas N, Jaouadi K, Gorcii M, Pratlong F, Dedet JP, et al. Usefulness of a PCR-based method in the detection and species identification of Leishmania from clinical samples. Pathol Biol. 2012;60(6):e75-79.
doi: 10.1016/j.patbio.2011.11.011
pubmed: 22326417
Vázquez-Piñeiro T, Fernández Alvarez JM, Gonzalo Lafuente JC, Cano J, Gimeno M, Berenguer J. Visceral leishmaniasis: a lingual presentation in a patient with HIV infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86(2):179–82.
doi: 10.1016/S1079-2104(98)90122-6
pubmed: 9720093
Nigro L, Montineri A, La Rosa R, Zuccarello M, Iacobello C, Iacobello C, Vinci C, Pulizia R, Fatuzzo F. Visceral leishmaniasis and HIV co-infection: a rare case of pulmonary and oral localization. Infez Med. 2003;11(2):93–6.
pubmed: 15020853
Montineria A, La Rosaa R, Laroccaa L, Brisolesea V, Brancatia G, Fatuzzoa F, Nigrob L. Gingival ulcers as first manifestation of leishmaniasis and HIV infection. AIDS. 2008;22(1):160–1.
doi: 10.1097/QAD.0b013e3282f197b9
Kumar P, Sharma PK, Jain RK, Gautam RK, Bhardwaj M, Kar HK. Oral ulcer as an unusual feature of visceral leishmaniasis in an AIDS patient. Indian J Med Sci. 2007;61(2):97–101.
doi: 10.4103/0019-5359.30350
pubmed: 17259689
Rodrigo LM, Sierra JO, Jiménez ADA, Fernández IR. Oro-pharyngeal mass in a patient with HIV infection. Acta Otorrinolaringol Esp. 2008;59(4):202–3.
Presmanes MM, Cabedo GT, Cavero FV, Pastor GP, Santander RL. Lip ulceration due to visceral leishmaniasis in a HIV-positive patient. Med Cutan Iber Lat Am. 2008;36(4):195–8.
Rosenthal E, Marty P, del Giudice P, Pradier C, Ceppi C, Gastaut JA, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis. 2000;31:1093–5.
doi: 10.1086/318135
pubmed: 11049794
Gabriele G, Cascino F, Funaioli F, Gennaro P. Granulomatous cheilitis: differential diagnosis in patients with macrocheilia. BMJ Case Rep. 2023;16(5): e251829. https://doi.org/10.1136/bcr-2022-251829 .
doi: 10.1136/bcr-2022-251829
pubmed: 37221004
Mohammadpour I, Motazedian MH, Handjani F, Hatam GR. Lip leishmaniasis: a case series with molecular identification and literature review. BMC Infect Dis. 2017;17(1):96. https://doi.org/10.1186/s12879-016-2178-7 .
doi: 10.1186/s12879-016-2178-7
pubmed: 28122496
pmcid: 5264488
Takele Y, Mulaw T, Adem E, Shaw CJ, Franssen SU, Womersley R, Kaforou M, Taylor GP, Levin M, Müller I, Cotton JA, Kropf P. Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV. Cell Rep Med. 2021;3(1): 100487. https://doi.org/10.1016/j.xcrm.2021.100487 .
doi: 10.1016/j.xcrm.2021.100487
pubmed: 35106507
pmcid: 8784791
Guedes DL, Justo AM, Barbosa Júnior WL, Silva EDD, Aquino SR, Lima Junior MSDC, Montarroyos U, Bezerra GSN, Vieira AVB, Pereira VRA, Medeiros ZM. Asymptomatic Leishmania infection in HIV-positive outpatients on antiretroviral therapy in Pernambuco, Brazil. PLoS Negl Trop Dis. 2021;15(1): e0009067. https://doi.org/10.1371/journal.pntd.0009067 .
doi: 10.1371/journal.pntd.0009067
pubmed: 33476331
pmcid: 7853496
Molina R, Jiménez M, García-Martínez J, San Martín JV, Carrillo E, Sánchez C, Moreno J, Alves F, Alvar J. Role of asymptomatic and symptomatic humans as reservoirs of visceral leishmaniasis in a Mediterranean context. PLoS Negl Trop Dis. 2020;14(4): e0008253. https://doi.org/10.1371/journal.pntd.0008253 .
doi: 10.1371/journal.pntd.0008253
pubmed: 32324738
pmcid: 7200008